Optimer Pharmaceuticals and Clinical Investigators to Present Data at Upcoming Medical Meetings
SAN DIEGO, April 28, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced that additional data from the DIFICID™ Phase 3 trials will be presented at the following medical meetings:
Digestive Disease Week (DDW), McCormick Place, Chicago, IL May 7-10, 2011 |
||
Poster Presentation Information: |
||
Title: |
Risk of Recurrence and Time to Recurrence Following Treatment of Clostridium |
|
difficile Infection: Patient Characteristics and the Differential Effect of Fidaxomicin |
||
vs. Vancomycin |
||
Presenter: |
Kathleen M. Mullane, D.O. |
|
Date: |
Saturday, May 7, 2011 |
|
Time: |
12:00 p.m. to 2:00 p.m. Central Time |
|
Location: |
Poster Session Hall A (MCP) |
|
Session: |
Intestinal Disorders: Prebiotics, Probiotics and Pathogens |
|
Program #: |
Sa1981 |
|
Poster Presentation Information: |
||
Title: |
High Fecal and Low Plasma Levels of Fidaxomicin and Metabolite OP-1118 in |
|
Patients with C. difficile infection: Combined Results of Two Phase 3 Trials |
||
Presenter: |
Pamela S. Sears, Ph.D. |
|
Date: |
Monday, May 9, 2011 |
|
Time: |
12:00 p.m. to 2:00 p.m. Central Time |
|
Location: |
Poster Session Hall A (MCP) |
|
Session: |
Randomized Controlled Clinical Trials |
|
Program #: |
Mo1160 |
|
European Congress of Clinical Microbiology and Infectious Diseases and International Congress of Chemotherapy, Milano Convention Center, Milan, Italy May 7-10, 2011 |
||
Oral Presentation Information: |
||
Title: |
Immunosuppression and the Risk of Death, Cure Rates and Disease Recurrence |
|
Among Patients with Clostridium difficile Infection |
||
Presenter: |
Yoav Golan, M.D., M.S. |
|
Date: |
Tuesday, May 10, 2011 |
|
Time: |
10:36 a.m. to 10:48 a.m. Central European Time |
|
Location: |
Lecture Hall Brown 1 |
|
Oral Session: |
C. difficile News |
|
Presentation #: |
O504 |
|
Poster Presentation Information: |
||
Title: |
Clostridium difficile Recurrence, Alcohol Consumption, and the Effect of |
|
Fidaxomicin vs. Vancomycin |
||
Presenter: |
Yoav Golan, M.D., M.S. |
|
Date: |
Tuesday, May 10, 2011 |
|
Time: |
12:30 p.m. to 1:30 p.m. Central European Time |
|
Location: |
Poster Area Hall 5 |
|
Poster Topic 99: |
Clostridium difficile |
|
Poster ID#: |
P1968 |
|
2011 Annual Scientific Meeting of the American Geriatrics Society (AGS), The Gaylord National Hotel, National Harbor, Maryland May 11-14, 2011 |
||
Poster Presentation Information: |
||
Title: |
Effect of Advancing Age on Outcomes of Therapy for Clostridium difficile Infection |
|
Presenter: |
Thomas J. Louie, M.D. |
|
Date: |
Thursday, May 12, 2011 |
|
Time: |
4:30 p.m. to 6:00 p.m. Eastern Time |
|
Session: |
Presidential Poster Session B |
|
Location: |
Exhibit Hall |
|
Poster ID#: |
B126 |
|
About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer has two anti-infective product candidates in development, DIFICID™ (fidaxomicin) and Pruvel™ (prulifloxacin). DIFICID is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI). The FDA granted the Company's request for six-month Priority Review of Optimer's NDA for DIFICID, and has assigned a Prescription Drug User Fee Act (PDUFA) goal date of May 30, 2011. The Company also filed a MAA with the European Medicines Agency (EMA) for DIFICID. Pruvel™ is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.
Contacts
Optimer Pharmaceuticals, Inc.
Christina Donaghy, Corporate Communications Manager
John D. Prunty, Chief Financial Officer & VP Finance
858-909-0736
Canale Communications
Jason I. Spark, Senior Vice President
619-849-6005
SOURCE Optimer Pharmaceuticals, Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article